(Q34660431)

3 August 2017

title

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting (English)

1 reference

metastatic renal cell carcinoma

3 August 2017

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Giovanni Lo Re

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Camillo Porta

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

7

Ugo De Giorgi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

19

Roberto Iacovelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Lisa Derosa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Angela Gernone

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Franco Morelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Teodoro Sava

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Fable Zustovich

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Vittorio Ferrari

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Roberto Sabbatini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Donatello Gasparro

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Alessandra Felici

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Luciano Burattini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Nicola Calvani

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Giuseppe Banna

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Maria Pia Brizzi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mimma Rizzo

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Libero Ciuffreda

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Francesco Ferraù

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Eleonora Taibi

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sergio Bracarda

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Enzo Galligioni

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Antonio Contu

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

18 March 2014

1 reference

3 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

1741-1750

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24641206%20AND%20SRC:MED&resulttype=core&format=json

Signaling inhibitors in metastatic renal cell carcinoma

10 June 2020

cites work

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial

21 January 2018

1 reference

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.

21 January 2018

1 reference

The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce

21 January 2018

1 reference

Experience with sorafenib in the treatment of advanced renal cell carcinoma.

21 January 2018

1 reference

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis

21 January 2018

1 reference

Treating patients with metastatic renal carcinoma: an escape from Phase III.

21 January 2018

1 reference

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

21 January 2018

1 reference

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

21 January 2018

1 reference

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort

21 January 2018

1 reference

Advanced kidney cancer: treating the elderly

21 January 2018

1 reference